Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$44.49-6.10%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
QuarterlyIQ Insights · LQDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 25.8% |
| Our one-year growth estimate | diamond | 57.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 31.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 1 industry peers · Company calendar date is not available
LQDA — litigation filed
Dated 2026-10-13
Entry into a Material Definitive Agreement. Settlement Agreement On October 13, 2026 (the “Effective Date”), Liquidia Technologies, Inc., a Delaware corporation (the “Company”), a wholly-owned subsidiary of Liquidia Corporation, and United Therapeutics Corporation (“UTC”) entered into a settlement agreement (the “Settlement Agreement”) regarding all ongoing litigation between the Company and UTC, including, among other matters, the resolution of pending patent infringement litigations relatin…
Why it matters: The payment is due while Liquidia also funds its business and clinical studies. Cash after payment will show how much room remains.
Worry ifA company filing confirms the $72.7 million payment was made by Jan. 31, 2027, with cash and cash equivalents still reported above $300 million.
Less concerning ifThe payment is late, or cash and cash equivalents fall below $300 million after payment.
Why it matters: Q3 sales set the latest pace for YUTREPIA after strong growth. Higher sales can help fund settlement payments and studies.
Supportive ifThe Nov. 2 earnings report confirms Q3 YUTREPIA net product sales at or above the preliminary $222.7 million.
Worry ifThe Nov. 2 report puts Q3 YUTREPIA net product sales below $222.7 million.
Why it matters: Liquidia agreed to remove PH-ILD from the label and stop promoting YUTREPIA for it. The FDA decision will confirm the new label status.
Worry ifThe FDA approves the label change. Company materials list YUTREPIA only for PAH.
Less concerning ifThe FDA has not approved the label change by the next quarterly report, or the label keeps PH-ILD.
Why it matters: Re-Spire is the pivotal L606 study for PH-ILD. Continued enrollment marks progress on a key clinical program.
Supportive ifThe next company update says Re-Spire sites are enrolling patients. It reports no pause.
Worry ifLiquidia reports a Re-Spire enrollment pause, study delay, or a stop to the trial.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $567 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,154 loss on $10,000 · 71.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.